Role of Toll-like receptors in cervical, endometrial and ovarian cancers: A review

Gynecologic Oncology

Volumn 135, Issue 2, 2014, Pages 359-363

  Husseinzadeh, Nader ^a   Davenport, Sara Madison ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cervical, endometrial, ovarian cancers; Gynecologic cancer; Toll like receptors

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR AGONIST;

CANCER ADJUVANT THERAPY; CELL ACTIVATION; CELL SURVIVAL; ENDOMETRIUM CANCER; HUMAN; NATURAL KILLER CELL; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; ADENOCARCINOMA; AGONISTS; CARCINOMA; CARCINOMA, SQUAMOUS CELL; ENDOMETRIAL NEOPLASMS; FEMALE; IMMUNOLOGY; OVARIAN NEOPLASMS; PAPILLOMAVIRUS INFECTION; UTERINE CERVICAL NEOPLASMS;

ADENOCARCINOMA; CARCINOMA; CARCINOMA, SQUAMOUS CELL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; TOLL-LIKE RECEPTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84913612246     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.08.013     Document Type: Review

References (43)

1. K. Takeda, T. Kaisho, and S. Akira Toll-like receptors Annu Rev Immunol 21 2003 335 376
2. K. Takeda, and S. Akira Toll-like receptors in innate immunity Int Immunol 17 2005 1 14
3. T. Kawai, and S. Akira The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Nat Immunol 11 2010 373 384
4. C.A. Janeway Jr., and R. Medzhitov Innate immune recognition Annu Rev Immunol 20 2002 197 216
5. H. Kanzler, F.J. Barrat, E.M. Hessel, and R.L. Coffman Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists Nat Med 13 2007 552 559
6. L. Verstepen, T. Bekaert, T.L. Chau, J. Tavemier, A. Chariot, and R. Beyaert TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme Cell Mol Life Sci 65 2008 2964 2978
7. B.B. Aggarwal Signaling pathways of the TNF superfamily: a double edged sword Nat Rev Immunol 134 2003 437 444
8. S. Basith, B. Manavalan, T.H. Yoo, S.G. Kim, and S. Choi Roles of toll-like receptors in cancer: a double-edged sword for defense and offense Arch Pharm Res 35 2012 1297 1316
9. S. Rakoff-Nahoum, and R. Medzhitov Toll-like receptors and cancer. Perspectives Nat Rev Cancer 9 2009 57 63
10. P. Carmeliet VEGF as a key mediator of angiogenesis in cancer Oncology 69 3 2005 4 10
11. L.A. Ridnour, R.Y.S. Cheng, C.H. Switzer, J.L. Heinecke, S. Ambs, and S. Glynn Molecular pathways: toll-like receptors in the tumor microenvironment-poor prognosis or new therapeutic opportunity Clin Cancer Res 19 2013 1340 1346
12. Y. Sato, Y. Goto, H. Narita, and D.S. Hoon Cancer cells expressing toll-like receptors and the tumor microenvironment Cancer Microenviron 2 1 2009 205 214
13. M.S. Sheikh, and Y. Huang Death receptor activation complexes: it takes two to activate TNF receptor 1 Cell Cycle 2 2003 550 552
14. R.O. Escarcega, S. Fuentes-Alexandro, M. Garcia-Carrasco, A. Gatica, and A. Zamora The transcription factor NF-κB and cancer Clin Oncol 19 2007 154 161
15. A. Fazeli, C. Bruce, and D.O. Anumba Characterization of toll-like receptors in the female reproductive tract Hum Reprod 20 2005 1372 1378
16. C. Bodelon, M.M. Madeleine, L.G. Johnson, Q. Du, D.A. Galloway, and M. Malkki Genetic variation in the TLR and NF-κB pathways and cervical and vulvar cancer risk: a population based case control study Int J Cancer 134 2014 437 444
17. J. Werner, C.A. Decarlo, N. Escott, I. zehbe, and M. Ulanova Expression of integrins and toll-like receptors in cervical cancer: effect of infectious agents Innate Immun 18 2012 55 69
18. M. Nishimura, and S. Naito Tissue specific mRNA expression profiles of human toll like receptors and related genes Biol Pharm Bull 28 2005 886 892
19. J.W. Lee, J.J. Choi, E.S. Seo, M.J. Kim, W.Y. Kim, and C.H. Choi Increased toll-like receptor 9 expression in cervical neoplasia Mol Carcinog 46 2007 941 947
20. L. Yu, L. Wang, M. Li, J. Zhong, Z. Wang, and S. Chen Expression of toll-like receptor 4 is downregulated during progression of cervical neoplasia Cancer Immunol Immunother 59 2010 1201 1208
21. U.A. Hasan, E. Bates, F. Takeshita, A. Biliato, R. Accardi, and V. Bouvard TLR-9 expression and function is abolished by the cervical cancer associated HPV type 16 J Immunol 178 2007 3186 3197
22. W.Y. Kim, J.W. Lee, J.J. Choi, T.J. Kim, B.J. Ki, and S.Y. Song Increased expression of toll like receptor 5 during progression of cervical neoplasia Int J Gynecol Cancer 18 2008 300 305
23. S. Allorn, C. Böing, A.A. Koch, R. Kimming, and I. Gashaw TLR3 and TRL4 expression in healthy and diseased human endometrium Reprod Biol Endocrinol 6 2008 40 10.1186/1477-7827-6-40
24. K.A. Ashton, A. Proietto, G. Otton, I. Symonds, M. McEvoy, and J. Attia Toll-like receptor and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk BMC Cancer 10: 382 2010 10.1186/1471-2407-10-382
25. S. Rajput, and L.D. Volk-Draper Ran S.TLR 4 is a novel determinant of response to paclitaxel in breast cancer Mol Cancer Ther 12 2013 1676 1687
26. M. Zhou, M.M. McFarland-Mancini, H.M. Funk, N. Husseinzadeh, T. Mounajjed, and A. Drew Toll like receptor expression in normal ovary and ovarian tumors Cancer Immunol Immunother 58 2009 1375 1385
27. D.C. Woods, Y.A. White, C. Dau, and A.L. Johnson TLR4 activates NF-κB in human ovarian granulosa tumor cells Biochem Biophys Res Commun 409 2011 675 680
28. G. Peng, Z. Guo, Y. Kiniwa, K.S. Voo, W. Peng, and T. Fu Toll-like receptor 8-mediated reversal of CD4 + regulatory T cell function Science 309 2005 1380 1384
29. R. Berger, H. Fiegl, G. Goebel, P. Obexer, M. Ausserlechner, and W. Doppler Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors Cancer Sci 101 2010 1059 1066
30. H. Lu, G.N. Dietsch, M.A. Matthews, Y. Yang, S. Ghanekar, and M. Inokuma VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC Clin Cancer Res 18 2012 499 509
31. C.A. Byrd-Leifer, E.F. Block, K. Takeda, S. Akira, and A. Ding The role of MyD88 and TLR4 in the LPS - mimetic activity of Taxol Eur J Immunol 31 2001 2448 2457
32. M.G. Kelly, A.B. Alvero, R. Chen, D.A. Silasi, V.M. Abrahams, and S. Chan TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer Cancer Res 66 2006 3859 3868
33. M.A. Tichomirowa, M. Theodoropoulou, A.F. Daly, A. Yassouridis, S. Hansen, and J. Lu Toll-like receptor-4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel Int J Cancer 123 2008 1956 1963
34. T.J. Brueseke, and K.S. Tewari Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma Clin Pharmacol 5 2013 13 19
35. B. Monk TLR8 agonist VTX-2337 and pegylated liposomal doxorubicin hydrochloride or paclitaxel in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer (GOG3003) http://www.cancer.gov/clinicaltrials/Search/view?cdrid=695034&version [Health Professional (Accessed on 2/20/2014)]
36. M.A. Geller, S. Cooley, P.A. Argenta, L.S. Downs, L.F. Carson, and P.L. Judson Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers Cancer Immunol Immunother 59 2010 1877 1884
37. J. Vakkila, and M.T. Lotze Inflammation and necrosis promote tumor growth Nat Rev Immunol 4 2004 641 648
38. S. Gnjatic, N.B. Sawhney, and N. Bhardwaj Toll-like receptor agonists: are they good adjuvants? Cancer J 16 2010 382 391
39. S. Demaria, N. Bhardwaj, W.H. Mcbride, and S.C. Formenti Combining radiotherapy and immunotherapy: a revived partnership Int J Radiat Oncol Biol Phys 63 2005 655 666
40. L. Zitvogel, L. Apetoh, F. Ghiringhelli, F. Andre, A. Tesniere, and G. Kroemer The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118 2008 1991 2001
41. B. Salaun, I. Coste, M.C. Rissoan, S.J. Lebecque, and T. Renno TLR3 can directly trigger apoptosis in human cancer cells J Immunol 176 2006 4894 4901
42. S. Adams Toll-like receptor agonists in cancer therapy Immunology 1 2009 949 964
43. Y.M. Murad, and T.M. Clay CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer BioDrugs 23 6 2009 361 375